| Symbol | ADMA |
|---|---|
| Name | ADMA BIOLOGICS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biological Products, (No Diagnostic Substances) |
| Address | C/O ADMA BIOLOGICS, INC., RAMSEY, NJ 07446 |
| Telephone | (201) 478-5552 |
| Fax | — |
| — | |
| Website | https://www.admabiologics.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001368514 |
| Description | ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. Additional info from NASDAQ: |
ADMA Biologics, Inc. (ADMA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
Read moreADMA DEADLINE: The Gross Law Firm Reminds ADMA Biologics, Inc. Investors of Upcoming Securities Class Action Deadline
Read moreADMA Biologics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ADMA
Read moreADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
Read moreADMA Biologics, Inc. Notice of August 10, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Read moreKohler Terry 🟢 acquired 221.5K shares (1 derivative) of ADMA BIOLOGICS, INC. (ADMA) at $8.81 ($1.2M) Transaction Date: Jul 16, 2026 | Filing ID: 028844
Read moreADMA Biologics, Inc. Stock Drop: Robbins LLP Urges Investors to Contact the Firm for Information About the Class Action Against ADMA Biologics, Inc.
Read moreADMA INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that ADMA Biologics, Inc. Investors with Substantial Losses Have Opportunity to Lead ADMA Biologics Class Action Lawsuit
Read moreNASDAQ: ADMA CLASS ACTION NOTICE: Berger Montague Encourages ADMA Biologics, Inc. (NASDAQ: ADMA) Investors to Inquire About a Securities Fraud Class Action
Read moreINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ADMA Biologics, Inc. of Class Action Lawsuit and Upcoming Deadlines - ADMA
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05070455 | An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and… | Phase4 | Primary Immune Deficiency | Unknown | 2022-09-01 | 2023-06-30 | ClinicalTrials.gov |
| NCT03164967 | Study to Evaluate Safety and Pharmacokinetics of BIVIGAM® in Primary Immune Def… | Phase4 | Humoral Immune Response | Completed | 2016-12-29 | 2022-12-31 | ClinicalTrials.gov |
| NCT03037359 | A Study About Low Blood Pressure in Patients With Primary Immunodeficiency Dise… | — | Primary Immune Deficiency Disorder | Unknown | 2016-12-01 | 2023-06-30 | ClinicalTrials.gov |
| NCT01814800 | Pharmacokinetics, Efficacy, and Safety Study of RI-002 (IGIV) in Subjects With … | Phase3 | Primary Immune Deficiency Disorder | Completed | 2014-02-01 | 2015-01-01 | ClinicalTrials.gov |
| NCT00632463 | RI-001 in Immunosuppressed Respiratory Syncytial Virus (RSV) Infected Patients … | Phase2 | Upper Respiratory Tract Infection | Completed | 2008-02-01 | 2010-05-01 | ClinicalTrials.gov |
| NCT00538915 | Open Label, Phase III Study of NABI-IGIV 10% [Immune Globulin Intravenous(Human… | Phase3 | Primary Immune Deficiency Disorders (PIDD) | Completed | 2007-09-01 | 2009-07-01 | ClinicalTrials.gov |
| NCT00473824 | Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), C… | Phase2 | Sequelae of Viral Hepatitis | Terminated | 2007-05-01 | 2009-02-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| RI-002 | Other | Phase PHASE3 | Primary Immune Deficiency Disorder | COMPLETED | NCT01814800 |
| Asceniv™ | Other | Phase PHASE4 | Primary Immune Deficiency | UNKNOWN | NCT05070455 |
| Bivigam | Other | Phase PHASE4 | Humoral Immune Response | COMPLETED | NCT03164967 |
| Other | Other | Preclinical | Primary Immune Deficiency Disorder | UNKNOWN | NCT03037359 |
| Bivigam | Other | Preclinical | Primary Immune Deficiency Disorder | UNKNOWN | NCT03037359 |
| Asceniv™ | BIOLOGICAL | Phase PHASE4 | Primary Immune Deficiency | UNKNOWN | NCT05070455 |
| Other | BIOLOGICAL | Preclinical | Primary Immune Deficiency Disorder | UNKNOWN | NCT03037359 |
| Bivigam | BIOLOGICAL | Phase PHASE4 | Humoral Immune Response | COMPLETED | NCT03164967 |
| RI-002 | BIOLOGICAL | Phase PHASE3 | Primary Immune Deficiency Disorder | COMPLETED | NCT01814800 |
| Hepatitis C Immune Globulin Intravenous (Human) 5% | BIOLOGICAL | Phase PHASE2 | Sequelae of Viral Hepatitis | TERMINATED | NCT00473824 |
| RI-001 | BIOLOGICAL | Phase PHASE2 | Upper Respiratory Tract Infection | COMPLETED | NCT00632463 |
| Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%] | BIOLOGICAL | Phase PHASE3 | Primary Immune Deficiency Disorders (PIDD) | COMPLETED | NCT00538915 |